Hiberix Approval History
- FDA approved: Yes (First approved August 19th, 2009)
- Brand name: Hiberix
- Generic name: Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)
- Dosage form: Solution for Intramuscular Injection
- Company: GlaxoSmithKline
- Treatment for: Haemophilus influenzae Prophylaxis
Hiberix is a vaccine indicated for active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b. Hiberix is approved for use in children aged six weeks through four years of age (prior to fifth birthday).
Development History and FDA Approval Process for Hiberix
|Jan 14, 2016||FDA Approves Expanded Use of GSK Hib Vaccine From Booster Dose To Full Series|
|Aug 20, 2009||FDA Approves GSK's Hib Vaccine, Hiberix|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.